“The preliminary total revenue figure for 2019, consisting of product sales, Contract Research (CRO), training and services is 8.8 MSEK – that is a Year on Year growth of almost 62% compared to the same period in 2018 (5.4 MSEK)” says Manoush Masarrat, CEO of Inhalation Sciences AB. The revenue for ISAB’s product sales amounts to 7 MSEK. “This is by far an all-time high for the company” Masarrat says “and we aim to continue these record revenues in 2020”. The full 2019 Year-end Report will be published on February 20, as earlier communicated.